Good evening :)
$
₹
Caris Life Sciences, Inc. Common Stock

Caris Life Sciences, Inc. Common Stock

CAI

NASDAQ
Asset Logo

Caris Life Sciences, Inc. Common Stock

CAI

NASDAQ
$29.823.53% (-1.09)
$
₹
$29.823.53% (-1.09)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $8.0B the stock is ranked 1124

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

2.97
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

13.61
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$9.48
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

10.62%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Peers

Peers

Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
34.49
34.49
1Y Return
35.4%
35.4%
Buy Reco %
80.64
80.64
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
33.81
33.81
1Y Return
41.66%
41.66%
Buy Reco %
69.56
69.56
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
29.66
29.66
1Y Return
22.75%
22.75%
Buy Reco %
82.35
82.35
Waters Corporation
WAT
Waters Corporation
P/E Ratio
106.36
106.36
1Y Return
37.61%
37.61%
Buy Reco %
31.81
31.81
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
41.47
41.47
1Y Return
137.96%
137.96%
Buy Reco %
55.00
55.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Caris Life Sciences, Inc. Common Stock 2.9713.61-
Thermo Fisher Scientific Inc34.494.501.82
IQVIA Holdings Inc33.817.190.98

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

216.8
24.3
292.8
81.9
216.1
-0.5
263.7
-0.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue80.67100.04101.62129.91120.91181.39216.83292.88216.17263.71
Net Income-111.02-66.18-67.72-36.94-102.58-71.7924.3281.95-0.51-0.63
Net Profit Margin-137.62%-66.15%-66.64%-28.43%-84.83%-39.57%11.21%27.98%-0.23%-0.24%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Caris Life Sciences, Inc. Common Stock (CAI) share price today is $29.82 as of September 19, 2026 at 1:30 AM IST. The stock touched a day high of $30.91 and a day low of $29.70.

  2. Caris Life Sciences, Inc. Common Stock stock trades on NASDAQ under the ticker symbol CAI.

  3. Caris Life Sciences, Inc. Common Stock's market capitalization is $7.97B as of September 19, 2026 at 1:30 AM IST.

  4. Caris Life Sciences, Inc. Common Stock's price-to-earnings (P/E) ratio is 2.97 as of September 18, 2026.

  5. Caris Life Sciences, Inc. Common Stock's price-to-book (P/B) ratio is 13.61 as of September 18, 2026.

  6. Yes, You can buy Caris Life Sciences, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Caris Life Sciences, Inc. Common Stock shares in three steps: 1. Search Caris Life Sciences, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Caris Life Sciences, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Caris Life Sciences, Inc. Common Stock (CAI) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3352 shares at the current price of $29.82.

Loading...